Big Data Analytics (BDA) is opening doors when it comes to minimizing expenses, saving time, improving patient health and advancing precision medicine. Unlocking phi for BDA is no easy feat. Risk-based de-identification not only leaves organizations with high quality, usable data, but it preserves patient anonymity and compliance with global regulations. Learn how your organization can benefit by using the world’s only de-identification method built on HIPAA’s Statistical Method.
Risk-based De-identification Enables Big Data Analytics
Many of the challenges hurting BDA can be solved by using risk-based de-identification software
DOWNLOAD THE DATASHEET
Benefits of BDA
BDA can address problems in healthcare, like medication non-adherence, by revealing patterns and trends in the data of large population datasets and applying these insights to individual patients. Analysis can reveal predictors of certain behaviors so that it is possible to identify other patients that are at high risk for these same behaviors. By identifying at risk patients early, it is possible to put strategies in place to change the detrimental behavior and improve medical outcomes.
Limit the risks, but not the rewards when enabling Big Data Analytics for your organization.
Unlocking PHI for Secondary Use
WATCH THE WEBINAR
By integrating automated de-identification into our work flow, you can turn the vast stores of PHI into high quality data for research and analytics – without compromising patient privacy.
ASCO CancerLinQ has created the world’s first oncology learning system. By linking hospital and clinic data and using risk-based de-identification, they put massive amounts of real data in the hands of doctors and researchers. This data can improve patient treatment, improve outcomes and increase the speed of new cancer drug research.GET THE ASCO CASE STUDY